Ide T, et al. - Researchers here used a pharmacokinetics/pharmacokinetics (PK/PD) approach to determine the optimum dosing regimen of linezolid in sepsis patients with and without renal dysfunction and sepsis patients on low-dose continuous renal replacement therapy (CRRT). For patients with preserved renal function, the proposed regimen to attain cumulative fraction of response (CFR) ≥ 90% was 800 mg every 12 h (safety probability 82.4%). However, in patients with renal dysfunction and those on CRRT, the target CFR was attained with a decreased regimen [600 mg every 24h (safety probability 68.6%) and 800 mg every 24h (42.1%)]. Because of unassured safety probability, they recommended adjusting dosing regimens based on the therapeutic drug monitoring in patients without preserved renal function.